Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Immunosuppressants Stories

2013-09-10 08:28:41

European Commission approval is a significant milestone for availability of lower-cost biologic therapy LEAMINGTON SPA, England, Sept. 10, 2013 /PRNewswire/ -- Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra(TM) (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid...

2013-09-04 08:31:46

Veloxis Introduces Envarsus® as Trade Name for LCP-Tacro(TM) HORSHOLM, Denmark, Sept. 4, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the 3002, randomized, double-blind, double-dummy, Phase III study in 543 de novo kidney transplant patients will be presented at the European Society for Organ Transplantation as a late-breaker oral presentation at 8:30 a.m. CEST, Sept. 9, in Vienna. Veloxis' once-daily LCP-Tacro(TM), now with the trade...

2013-08-28 23:27:00

NWC Physicians praise Elan Pharmaceuticals for developing a vaccine that removes the buildup of beta-amyloid and plaque in the brain, restoring function without side effects in an 80 patient trial according to a recent report published in the Daily Mail*. (PRWEB) August 28, 2013 Research teams at the University of Edinburgh Medical School and University of Toronto Medical School report; "Not only were we able to clean up the brain tissue, but we also prevented the behavioral...

2013-08-27 23:28:42

Avail is conducting a randomized, Phase 3 study comparing the efficacy and safety of a new psoriasis drug with Etanercept and a placebo in patients with moderate-to-severe moderate-to-severe plaque psoriasis. DeLand, Florida (PRWEB) August 27, 2013 *To see if you qualify for this Psoriasis Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no insurance is required,...

2013-08-22 08:27:33

NORTHBROOK, Ill., Aug. 22, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that ASTAGRAF XL(TM) (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction, is now available in U.S. pharmacies. "The availability of ASTAGRAF XL marks a...

2013-08-21 23:26:56

NWC physicians respond to a recent WPTV* report that fails to mention that the memory; mood and cognitive function impairments of Alzheimer’s may be reversed to a degree that is meaningful and life changing. (PRWEB) August 21, 2013 Implementing the treatment detailed in Perispinal etanercept: a New Therapeutic Paradigm in Neurology** by Dr. Tobinick can enable a severely impaired person needing full time assisted living care who is unable to recognize their own children or even count to...

2013-08-14 23:25:12

Neurological Wellness Center physicians respond to a recent survey finding 37% of stroke survivors develop depression and report the alleviation of depression is a predictable outcome of perispinally administered Enbrel treatment for stroke. (PRWEB) August 14, 2013 An estimated 700,000 people have a stroke in the United States each year, and approximately 37% of stroke survivors develop depression within 2 years according to survey published in NewsFix*. Several studies have shown that...

2013-08-14 08:30:23

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2013 U.S. prescription sales data for the top 100 drugs. Since Q2 2012, Otuska's antipsychotic Abilify and AstraZeneca's acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each posts close to $1.5 billion in sales. Humira, AbbVie's key tumor necrosis factor (TNF)...

2013-07-31 23:35:53

Alzheimer's is by far the most expensive disease in America yet the National Institutes of Health (NIH) research budget for Alzheimer's is $484 million; in contrast, the cancer research budget is $5.6 billion. (PRWEB) July 31, 2013 In his State of the Union address President Obama called on congress to provide funding to "unlock the answers to Alzheimer's." The cost trajectory for this disease is staggering. "Nationwide, the total cost of caring for those with...

2013-07-26 11:22:02

Substance makes mice live longer, but hardly slows down the aging process The drug rapamycin is known to increase lifespan in mice. Whether rapamycin slows down aging, however, remains unclear. A team of researchers from the German Center for Neurodegenerative Diseases (DZNE) and the Helmholtz Zentrum München has now found that rapamycin extends lifespan - but its impact on aging itself is limited. The life-extending effect seems to be related to...